Cargando…
The role of erenumab in the treatment of migraine
Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of migraine symptoms, migraine-specific quality of l...
Autores principales: | Andreou, Anna P., Fuccaro, Matteo, Lambru, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257830/ https://www.ncbi.nlm.nih.gov/pubmed/32523630 http://dx.doi.org/10.1177/1756286420927119 |
Ejemplares similares
-
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
por: Andreou, Anna P., et al.
Publicado: (2022) -
A prospective real-world analysis of erenumab in refractory chronic migraine
por: Lambru, Giorgio, et al.
Publicado: (2020) -
Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021) -
Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020) -
Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)